A 30-minute Lunch & Learn with Prof. Arun Sanyal
Join us for a focused and informative Lunch & Learn session with one of the world’s foremost authorities on liver disease—Professor Arun Sanyal—as he breaks down the latest insights into identifying Metabolic Dysfunction-associated Steatohepatitis (MASH) patients at elevated risk of mortality.
You’ll gain practical, evidence-based tools to improve clinical outcomes through early and accurate identification of high-risk MASH patients.
Highlights
- ✅ Evaluate the latest diagnostic criteria and clinical guidelines for MASH.
- ✅ Analyze key risk factors and symptom patterns, including demographic and lifestyle indicators.
- ✅ Accurately interpret non-invasive tests and biomarkers, with an understanding of their specificity and sensitivity in MASH.
About the Speaker:
Prof. Arun Sanyal, M.D. is a world-renowned hepatologist and Professor of Medicine at Virginia Commonwealth University. With over 25 years of experience, he leads national and international efforts in liver disease research, including the NIH NASH Clinical Research Network and the NIMBLE consortium. Dr. Sanyal has authored more than 350 publications and played a pivotal role in shaping global practice guidelines for liver disease. His research continues to be supported by the NIH since 1995, and he is a past president of the American Association for the Study of Liver Diseases.
Save your spot today!
Continuing Education Information
This continuing education activity is provided by AffinityCE and MedAll. This activity provides continuing education credit for physicians, physician assistants, nurses, and nurse practitioners and pharmacists. A statement of participation is available to other attendees.
Faculty
Arun J. Sanyal, M.D.
Faculty Disclosures
Arun J. Sanyal
Consultant: Eli Lilly and Company, Echosens, Abbott, Promed, Genfit, Satellite Bio, Corcept, Arrowhead, Boston Pharmaceuticals, Variant, Cascade, 89Bio, AstraZeneca, Alnylam, Regeneron, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Histoindex, Janssen, Lipocine, Madrigal, Merck, Glaxo-Smith Kline, Novartis, Akero, Novo Nordisk, Path AI, Histoindex, Pfizer, Poxel, Salix, Myovant, Median technologies, Sequana, Surrozen, Takeda, Terns, and Zydus.
Institution has received grant support from AstraZeneca, Bristol-Myers Squibb, Gilead, Intercept, Mallinckrodt, Merck, Ocelot, Novartis, and Salix.
Royalties from Elsevier and UpToDate. He has stock options in Duret, Genfit, Tizsiana, Inversago.
No unapproved product related discussions to disclose.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Pharmacists Accreditation coming soon
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs
There is no cost to participate in this program.
---
This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.
---
This activity is a re-run of the live webinar Diagnostic Updates in Metabolic Dysfunction-Associated Steatohepatitis. Participants who attended the live webinar and claimed credits should not claim credits for this activity.